SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA accelerated approval of Voceryq, a competing treatment for recurrent respiratory papillomatosis, has raised concerns about competition for Precigens PAPZIMEOS and prompted a sharp selloff. Traders debate the threat, weighing Inovios new approval against Precigens established commercial launch and full-approval status, while questioning how quickly the rival can commercialize and complete required follow-up studies.

Pepe (PEPE) is a cryptocurrency launched in 2023and operates on the Ethereum platform. Pepe has a current supply of 413,772,350,098,130.40630647. The last known price of Pepe is 0.00000495 USD and is up 9.16 over the last 24 hours. It is currently trading on 729 active market(s) with $1,489,033,091.54 traded over the last 24 hours. More information can be found at https://www.pepe.vip/.

Pepe

PEPE is drawing attention amid volatile, largely consolidating price action and repeated attempts to break above resistance. Bulls are buying dips and anticipating a breakout, while skeptics point to sharp pullbacks and weakness alongside Bitcoin as signs the rallies may fade.

World Liberty Financial (WLFI) is a cryptocurrency launched in 2025and operates on the Ethereum platform. World Liberty Financial has a current supply of 100,000,000,000 with 31,779,981,969 in circulation. The last known price of World Liberty Financial is 0.05006283 USD and is down -1.40 over the last 24 hours. It is currently trading on 491 active market(s) with $50,711,301.08 traded over the last 24 hours. More information can be found at https://www.worldlibertyfinancial.com/.

WorldFinancial

WLFI is drawing attention amid its steep underperformance and criticism over Trump-family crypto profits, with many traders calling the token a grift. Bullish posters counter that a bank charter and potential USD1 utility could support a recovery, though the timing and impact remain uncertain.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

DXYZ is drawing attention as a listed proxy for Anthropic, with traders focused on its S-1 and anticipated IPO as potential catalysts for the funds holdings and NAV. The reaction is divided: some still expect IPO-related gains, while others point to the muted share-price response, dilution concerns, and uncertainty over how closely DXYZs market price reflects NAV.

Select Sector SPDR Trust (The) - State Street Health Care Select Sector SPDR ETF

Health Care Select Sector SPDR Fund

Healthcare is drawing attention as a defensive-sector rotation, with XLV outperforming the broader market and technology amid weakness in chips and other growth names. Traders point to broad strength and fresh highs across healthcare holdings, though some caution that the rally may be extended or vulnerable to a pullback.

BNB (BNB) is a cryptocurrency . BNB has a current supply of 131,511,387.69. The last known price of BNB is 703.59425696 USD and is up 0.47 over the last 24 hours. It is currently trading on 3523 active market(s) with $2,735,089,335.64 traded over the last 24 hours. More information can be found at https://bnbchain.org/en.

Binance

Binances reported major security breach and temporary withdrawal suspension dominate discussion, raising fears about customer fund safety, exchange solvency, and possible insider involvementthough the latter remains speculation. Some traders question why BNB has not fallen further and view its relative resilience as a reason to buy the dip.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is selling off after earnings despite beating expectations and raising its full-year outlook, as traders focus on a slower near-term growth outlook and reports that a major AI customer is reducing usage. The debate centers on whether this reflects temporary customer optimization or a broader demand slowdown, with the stocks rich valuation adding to concerns.

Amp (AMP) is a cryptocurrency launched in 2020and operates on the Ethereum platform. Amp has a current supply of 99,720,267,351.28921674 with 89,781,193,103.18022 in circulation. The last known price of Amp is 0.0006528 USD and is up 0.85 over the last 24 hours. It is currently trading on 193 active market(s) with $5,174,420.89 traded over the last 24 hours. More information can be found at https://amp.xyz.

AMP Token

A sharp price and volume surge has put AMP in focus, with traders highlighting its strength amid a weaker crypto market and watching for a breakout. Some speculate the move reflects interest in Flexa, Anvil and crypto-payment infrastructure, while skeptics call it a recurring pump that could fade; no specific new catalyst is established.

Quant (QNT) is a cryptocurrency and operates on the Ethereum platform. Quant has a current supply of 14,881,364 with 12,072,738 in circulation. The last known price of Quant is 192.80527848 USD and is up 5.70 over the last 24 hours. It is currently trading on 411 active market(s) with $99,578,584.95 traded over the last 24 hours. More information can be found at https://quant.network/.

Quant

QNTs sharp rally and repeated moves around the $200 level have traders debating whether momentum and short covering in a thin market can sustain a breakout or whether the token will pull back. Bulls point to Quants anticipated role in tokenized banking and its Clearing House connection, while skeptics note the lack of a fresh catalyst and continued resistance.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOne is drawing attention as investors focus on rising AI-driven cyber threats and the companys new autonomous security products, with recent analyst upgrades and positive customer feedback adding to the bullish discussion. Traders see the stock as undervalued relative to cybersecurity peers and speculate about a takeover, while others question its ability to sustain momentum and point to earnings and financing-related risks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law FirmPR NewswireNEW YORK, Oct. 12, 2026NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether...

Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm PR Newswire NEW YORK, Aug. 19, 2026 NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether...

CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates

CG Oncology, Inc. (CGON) delivered earnings and revenue surprises of -28.57% and -59.02%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Biotech Stocks Need A Shot In The Arm After Brutal July: Could AstraZeneca-Bristol Myers Megadeal Be The Cure?

Equity

A potential AstraZeneca-Bristol Myers deal worth $400 billion would create one of the world’s largest drugmakers and combine major cancer franchises.

CG Oncology Stock Gains 12% in Three Months: What's Driving It?

CGON climbs as cretostimogene nears a planned 2026 BLA filing, posts encouraging phase II data. It maintains a cash position that supports operations through 2029.

The New Cancer Moonshot: Innovative Companies Pursuing Game-Changing Therapies

Cancer treatment is undergoing one of the most significant transformations in modern medical history.

RBC Capital Lifts PT on CG Oncology (CGON), Calls PIVOT-006 a Complex Catalyst

RBC Capital Lifts PT on CG Oncology (CGON), Calls PIVOT-006 a Complex Catalyst...

CG Oncology, Inc. (CGON) Reports Q1 Loss, Tops Revenue Estimates

CG Oncology, Inc. (CGON) delivered earnings and revenue surprises of -23.33% and +80.50%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Gilead Sciences (GILD) Tops Q1 Earnings and Revenue Estimates

Gilead (GILD) delivered earnings and revenue surprises of +7.68% and +0.95%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts Think CG Oncology, Inc. (CGON) Could Surge 29.78%: Read This Before Placing a Bet

The consensus price target hints at a 29.8% upside potential for CG Oncology, Inc. (CGON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic patients afflicted with bladder cancer. It offers cretostimogene, a product initially in clinical development for the treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC). The company was founded by Alex Yeung and Paul A. DeRidder on September 24, 2010 and is headquartered in Dallas, TX.

Cg Oncology Inc.

Neutral Sentiment

<ul class="summary-bullets"><li>The deal would mark a major role reversal for AstraZeneca, which rejected Pfizer’s 70 billion pound bid in 2014 and has since grown into an oncology powerhouse.</li><li>AstraZeneca could deepen its U.S. presence, while Bristol Myers could gain support against patent expirations.</li><li>AstraZeneca reported $14.1 billion in first-half cancer-drug revenue, and Bristol Myers emphasized Opdivo, Breyanzi, and ADCs.</li></ul>After the biotech sector's worst month in more than a year, a potential combination between AstraZeneca (AZN) and Bristol Myers Squibb (BMY) is putting oncology stocks back in focus.The&nbsp;<a href="https://stocktwits.com/symbol/XBI">SPDR S&amp;P Biotech ETF (XBI)</a> fell 7% in July, marking its worst monthly performance since March 2025.<img src="https://news.stocktwits-cdn.com/xbi_524050cb07.png" alt="xbi.png"><h2 class="st-heading-2">Why Bristol Myers Fits AstraZeneca&nbsp;</h2>A&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/e9027253-e13c-460a-a4b1-f9047e5a6ca7?syn-25a6b1a6=1">reported</a> tie-up would create one of the world's largest pharma companies worth nearly $400 billion and unite two huge cancer-drug franchises spanning checkpoint inhibitors, lung cancer, blood cancers, and antibody-drug conjugates (ADCs).&nbsp;Twelve years ago, AstraZeneca was the takeover target after Pfizer launched a 70 billion pound bid that the former ultimately rejected under CEO Pascal Soriot. At the time, the company was grappling with late-stage pipeline disappointments. Today, AstraZeneca&nbsp;has turned into a buyer.The British drugmaker has grown into an oncology powerhouse with an ambitious goal of reaching $80 billion in annual revenue by 2030, compared with $58.7 billion last year. Nearly half of its revenue already comes from the U.S., making Bristol Myers an attractive way to deepen its commercial footprint in the world's largest pharma market. The transaction would also dwarf AstraZeneca's $39 billion Alexion acquisition in 2021, currently the biggest deal in its history. Even so, Soriot emphasized during last week's earnings call that AstraZeneca does not "need M&amp;A to deliver" its 2030 ambitions, underscoring that any transaction would be strategic rather than necessary.For Bristol Myers, the company is battling looming patent expirations and has struggled to convince investors that its $74 billion Celgene acquisition generated the expected long-term returns.&nbsp;<h2 class="st-heading-2">Oncology Takes Center Stage&nbsp;</h2>The timing of the report is notable as both companies highlighted in last week's earnings calls that cancer&nbsp;is their primary growth engine. AstraZeneca reported first-half oncology revenue of $14.1 billion, up 15%, driven by blockbuster medicines including Tagrisso, Calquence, Imfinzi, Enhertu and Datroway. Calquence surpassed $1 billion in quarterly sales for the first time, while Imfinzi and Imjudo revenue&nbsp;surged by 25%.AstraZeneca also highlighted positive Phase 3 data across bladder and gastric cancer, reinforcing AstraZeneca's stance that combining immunotherapy with ADCs could become a long-term growth driver.Meanwhile, Bristol Myers pointed to Opdivo, Breyanzi, its expanding hematology portfolio, and its ADC pipeline as pillars of growth. It also announced another Phase 3 lung-cancer study and said recent data boosted confidence in its ADC platform. CEO Chris Boerner also reiterated that business development remains a capital-allocation priority. "If those things come together and ideally continue to enable us to de-risk our near-term growth profile, we certainly have the financial flexibility and the capabilities to be in the mix," Boerner told investors.<h2 class="st-heading-2">Cancer-Drug Overlap Clouds The Deal</h2>The merger’s biggest attraction may also be its greatest obstacle. Bristol Myers’ Opdivo and AstraZeneca’s Imfinzi are rival checkpoint inhibitors used across lung cancer and other solid tumors, with both companies pushing into earlier treatment settings and combination regimens.That overlap is likely to draw antitrust scrutiny. BMO Capital Markets warned that the companies’ “significant business overlap” in oncology could lower the chances of a deal. However, any required divestitures, or decisions to cut overlapping pipeline programs, could create openings for competitors and smaller biotech firms.<h2 class="st-heading-2">Which Cancer Stocks Could Feel The Ripple Effects?</h2>Among retail favorites, ImmunityBio likely has the strongest connection to both companies. Its IL-15 agonist Anktiva has been studied with Bristol Myers’ Opdivo in the Quilt program and can complement checkpoint inhibitors by restoring immune-cell activity after resistance develops. The biotech firm also competes with AstraZeneca in bladder cancer, where both companies are pursuing bladder-preserving treatments in different patient populations.&nbsp;On the other hand, Sellas Life Sciences already has a clinical link to Bristol Myers. Its cancer vaccine, GPS, which targets a protein called WT1, was tested with Bristol Myers’ Opdivo in patients with malignant pleural mesothelioma, with Bristol Myers supplying the drug for the investigator-led study. GPS is now being evaluated in the Regal trial in acute myeloid leukemia (AML). Sellas is also developing SLS009, another treatment for hard-to-treat blood cancers, which is also an area where a combined AstraZeneca-Bristol Myers would already have expertise.Revolution Medicines is already working with Bristol Myers on a clinical trial combining Daraxonrasib, a drug that blocks cancer-driving RAS proteins, with BMS’ Navlimetostat. AstraZeneca has also been building its presence in the KRAS and RAS field, placing Revolution within an area of interest to both companies. CG Oncology, meanwhile, is developing Cretostimogene for bladder cancer in the same bladder-preservation market AstraZeneca is targeting with Imfinzi.&nbsp;Over the past year, XBI gained 72%, outperforming AZN’s 13% rise but trailing BMY’s 58% by a narrower margin. The biggest moves came from the smaller oncology stocks: SLS surged 530%, RVMD jumped 403%, IBRX rose 191%, and CGON gained 167%, all far outpacing the broader biotech ETF.&nbsp;<img src="https://news.stocktwits-cdn.com/cancer_stocks_9548cd4aaf.png" alt="cancer stocks.png"><h2 class="st-heading-2">How Do Retail Traders Feel About Cancer Stocks?</h2>Retail traders were most upbeat on the two large drugmakers. On Stocktwits, sentiment for BMY was ‘extremely bullish’ with ‘high’ message volume, while AZN and IBRX both drew ‘bullish’ sentiment amid ‘high’ chatter.Interest was more subdued elsewhere: SLS sentiment was ‘bearish’ with ‘low’ message volume, RVMD was ‘neutral’ with ‘low’ activity, and CGON was ‘neutral’ amid ‘normal’ message volume.One user&nbsp;<a href="https://stocktwits.com/kpopinvestor/message/660708093">said</a> that an AZN-BMY merger could create even more value by acquiring SLS, adding that Sellas’ GPS and SLS009 programs could potentially be combined with drugs such as Opdivo, Imfinzi, Tagrisso and other cancer treatments.<stembedurl>https://stocktwits.com/kpopinvestor/message/660708093</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/arnolddiver/message/660709098">said</a> that an AZN-BMY deal could increase ImmunityBio’s strategic appeal, as looming Opdivo patent losses may increase interest in Anktiva’s lung-cancer potential.&nbsp;<stembedurl>https://stocktwits.com/arnolddiver/message/660709098</stembedurl>For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/default/equity/why-retail-traders-couldn-nott-take-their-eyes-off-these-stocks-last-week-aapl-msft-amzn-meta-tsla/cZoRDhIRJ5m">Why Retail Traders Couldn’t Take Their Eyes Off These Stocks Last Week: AAPL, MSFT, AMZN, META, TSLA&nbsp;</a>

The SPDR S&P Biotech ETF (XBI) fell 7% in July, marking its worst monthly performance since March 2025. | Image source: Getty Images

AstraZeneca PLC

Bristol-Myers Squibb Co.

ImmunityBio Inc

Revolution Medicines Inc

SELLAS Life Sciences Group Inc

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$64.68
Prev Close	$63.47
Open	$63.00
Dividend Yield	0.00%
50-Day Moving Average	$69.43
Beta	1.47
Avg. Volume	977,653.31
PE Ratio	-24.00

52-Week High	$80.97
52-Week Low	$35.80
Market Capitalization	$5.73B
EPS (Annual)	-$2.08
Price to Book	5.55
Revenue Per Employee	$28,450.70

Feed

News

Sentiment

Earnings

Fundamentals

Info

CGON Fundamentals